Topamax and Gastrointestinal inflammation - a phase IV clinical study of FDA data
Gastrointestinal inflammation is found among people who take Topamax, especially for people who are female, 50-59 old, have been taking the drug for 10+ years.
The phase IV clinical study analyzes which people take Topamax and have Gastrointestinal inflammation. It is created by eHealthMe based on reports of 48,071 people who have side effects when taking Topamax from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.
48,071 people reported to have side effects when taking Topamax.
Among them, 21 people (0.04%) have Gastrointestinal inflammation.
What is Topamax?
Topamax has active ingredients of topiramate. It is often used in migraine. eHealthMe is studying from 52,605 Topamax users for its effectiveness, alternative drugs and more.
What is Gastrointestinal inflammation?
Gastrointestinal inflammation (inflammation of stomach and intestine) is found to be associated with 765 drugs and 503 conditions by eHealthMe.
Number of Topamax and Gastrointestinal inflammation reports submitted per year:
Time on Topamax when people have Gastrointestinal inflammation *:
- < 1 month: 0.0 %
- 1 - 6 months: 0.0 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 0.0 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 100 %
Gender of people who have Gastrointestinal inflammation when taking Topamax *:
- female: 76.19 %
- male: 23.81 %
Age of people who have Gastrointestinal inflammation when taking Topamax *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 26.67 %
- 30-39: 20.0 %
- 40-49: 20.0 %
- 50-59: 33.33 %
- 60+: 0.0 %
Common drugs people take besides Topamax *:
- Humira: 6 people, 28.57%
- Klonopin: 6 people, 28.57%
- Maxalt: 4 people, 19.05%
- Oxcarbazepine: 3 people, 14.29%
- Coumadin: 3 people, 14.29%
- Risperidone: 3 people, 14.29%
- Avelox: 3 people, 14.29%
- Prilosec: 3 people, 14.29%
- Wellbutrin: 3 people, 14.29%
- Nasonex: 3 people, 14.29%
Common side effects people have besides Gastrointestinal inflammation *:
- Nausea And Vomiting: 5 people, 23.81%
- Diarrhea: 4 people, 19.05%
- Abdominal Distension: 4 people, 19.05%
- Abdominal Pain: 4 people, 19.05%
- Heart Palpitations (feelings or sensations that your heart is pounding or racing): 4 people, 19.05%
- Pain: 3 people, 14.29%
- Local Swelling (swelling at the site of some application of substance or injury): 3 people, 14.29%
- Clostridial Infection (infectious conditions by clostridium bacteria): 3 people, 14.29%
- Feeling Abnormal: 3 people, 14.29%
- Nausea (feeling of having an urge to vomit): 3 people, 14.29%
Common conditions people have *:
- Crohn's Disease (condition that causes inflammation of the gastrointestinal tract): 7 people, 33.33%
- Abnormal Behavior: 3 people, 14.29%
- Stress And Anxiety: 3 people, 14.29%
- Sinusitis (inflammation of sinus): 3 people, 14.29%
- Headache (pain in head): 3 people, 14.29%
- Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 9.52%
- Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 9.52%
- Thrombosis (formation of a blood clot inside a blood vessel): 2 people, 9.52%
- High Blood Pressure: 2 people, 9.52%
- Asthma: 1 person, 4.76%
* Approximation only. Some reports may have incomplete information.
Do you take Topamax and have Gastrointestinal inflammation?Check whether Gastrointestinal inflammation is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Schwerd T, Pandey S, Yang HT, Bagola K, Jameson E, Jung J, Lachmann RH, Shah N, Patel SY, Booth C, Runz H, "Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann–Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn9s disease", Gut, 2016 Mar .
- Baloch M, Siddiqui MA, "Topiramate induced sudden loss of vision", JPMA, 2012 Oct .
- Kocamaz, M., & Karadag, O., "Topiramate-Induced Acute Myopia, Diplopia, and Photosensitivity: A Case Report", Beyoglu Eye Journal, 2019 Jan .
Alternative drugs to, pros and cons of Topamax:
- Topamax (52,605 reports)
Gastrointestinal inflammation treatments and more:
- Gastrointestinal inflammation (6,885 reports)
COVID vaccines that are related to Gastrointestinal inflammation:
- Gastrointestinal inflammation in Moderna COVID Vaccine
- Gastrointestinal inflammation in Pfizer BioNTech Covid Vaccine
- Gastrointestinal inflammation in Johnson and Johnson Covid Vaccine
How severe was Gastrointestinal inflammation and when was it recovered:
Expand to all the drugs that have ingredients of topiramate:
Common drugs associated with Gastrointestinal inflammation:
All the drugs that are associated with Gastrointestinal inflammation:
- Gastrointestinal inflammation (765 drugs)
Common conditions associated with Gastrointestinal inflammation:
All the conditions that are associated with Gastrointestinal inflammation:
- Gastrointestinal inflammation (503 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on topiramate (the active ingredients of Topamax) and Topamax (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Eliquis and Non-Hodgkin'S Lymphoma - now
- Apidra Solostar and Repaglinide drug interaction - a second ago
- Gemcitabine Hydrochloride and Decadron drug interaction - 6 seconds ago
- Sandostatin Lar and Cognitive Disorder - 6 seconds ago
- Camptosar and Skin Blushing/Flushing - 8 seconds ago